Position in DNLI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,216,594
New position
Shares Held
125,062
first reported quarter
Ownership
0.078%
of shares outstanding
% of Portfolio
0.53%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Odyssean, LLC holds $61,627,104 across 27 Biotechnology names. DNLI ranks #8 (5.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RARE |
Ultragenyx Pharmaceutical Inc.
|
122,087 | $4,076,484 | |
| 2 | KYMR |
Kymera Therapeutics, Inc.
|
34,485 | $3,954,394 | |
| 3 | IDYA |
IDEAYA Biosciences, Inc.
|
102,582 | $3,823,231 | |
| 4 | PCVX |
Vaxcyte, Inc.
|
62,638 | $3,641,146 | |
| 5 | CLDX |
Celldex Therapeutics, Inc.
|
95,069 | $3,537,517 | |
| 6 | MIRM |
Mirum Pharmaceuticals, Inc.
|
29,924 | $3,503,202 | |
| 7 | KRYS |
Krystal Biotech, Inc.
|
9,349 | $3,474,742 | |
| 8 | DNLI |
Denali Therapeutics Inc.
This page
|
125,062 | $3,216,594 |
All Filings in DNLI
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,216,594 | 125,062 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||